Annual Report

Overview

The report covers the Group's 2020 performance, including consolidated operating income of RMB10,520.41 million and continued growth in APIs and intermediates. It highlights COVID-19 diagnostic products alongside R&D across innovative medicines, biologics, APIs and diagnostics. It also describes the establishment of an Environmental, Social and Governance Committee under the Board and extensive environmental, safety and social-responsibility activities.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: 1 January 2020 – 31 December 2020
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services